The results of the GAUSS-3 trial were recently presented at the American College of Cardiology 65th Scientific Session & Expo and were published online in the Journal of the American Medical Association. How did the PCSK9 inhibitor perform among patients with statin intolerance? Was it found to be cost effective? Read more here. (Source: First Report Managed Care, 4/4/16)
You are here: / / PCSK9 Inhibitors – Does the Benefit Outweigh the Cost?